Not bad but you need a mutation!
The trial enrolled 134 heavily pre-treated mCRPC patients who had progressed after at least one novel hormonal agent and one taxane chemotherapy. Among these patients, 66 had activating mutations in the androgen receptor ligand-binding domain (AR-LBD), known to confer resistance to standard treatments like abiraterone and enzalutamide.
Results indicated that patients with AR-LBD mutations experienced higher response rates. Specifically, 53% achieved a PSA50 response (a reduction of at least 50% in prostate-specific antigen levels), compared to 15% in patients without these mutations. Objective tumor responses were also more frequent in the AR-LBD mutated group (19% vs. 5%). Interestingly, the proportion of patients achieving prolonged disease control beyond six months was similar in both groups, although the data are still maturing.
Safety profiles were manageable, with nearly all patients reporting adverse events, but 86% were mild to moderate (grade 1–2).
Zytiga: "Phase II pilot study of the prednisone to dexamethasone switch ..."
Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)
